Roche Holding AG's experimental leukemia drug shrank tumors in more patients when added to chemotherapy, according to study results that may aid the company in expanding its line of blood-cancer treatments.
http://washpost.bloomberg.com/Story?docId=1376-MMUMS66K513401-6GB4K3149N6L7EFN0I4EI6748F
http://washpost.bloomberg.com/Story?docId=1376-MMUMS66K513401-6GB4K3149N6L7EFN0I4EI6748F
No comments:
Post a Comment